| Medical Mutual | Rituximab: Rituxan®, Truxima®, Ruxience®, Riabni® (Intravenous) (EOV) | 2026-01-01 |
| Medical Mutual | Tecelra® (afamitresgene autoleucel) (Intravenous) (EOV) | 2026-01-01 |
| Medical Mutual | Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) (EOV) | 2026-01-01 |
| Medical Mutual | Tecentriq® (atezolizumab) (Intravenous) (EOV) | 2026-01-01 |
| Medical Mutual | Tevimbra® (tislelizumab-jsgr) (Intravenous) (EOV) | 2026-01-01 |
| Medical Mutual | Trodelvy® (sacituzumab govitecan-hziy) (Intravenous) (EOV) | 2026-01-01 |
| Medicare CGS | Oral Anticancer Drugs - Policy Article (52479) | 2025-12-31 |
| Medicare CGS | Oral Antiemetic Drugs (Replacement for Intravenous Antiemetics) - Policy Article (52480) | 2025-12-31 |
| Medicare Noridian | Oral Anticancer Drugs - Policy Article (52479) | 2025-12-31 |
| Medicare Noridian | Oral Antiemetic Drugs (Replacement for Intravenous Antiemetics) - Policy Article (52480) | 2025-12-31 |